COMMUNIQUÉS West-GlobeNewswire

Nicox signe un accord de licence avec Eyevance pour la commercialisation de ZERVIATE aux Etats-Unis.
21/09/2017
Communiqué de presse Nicox signe un accord de licence avec Eyevance pour la commercialisation de ZERVIATE TM aux Etats-Unis. Nicox recevra 6 millions de dollars à la signature, jusqu'à 42,5 millions de dollars de [...]
Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATETM in the United States
21/09/2017
Press Release Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATE TM in the United States Nicox to receive $6 million upfront payment and up to an additional $42.5 million in future [...]
Mithra Pharmaceuticals: MITHRA ANNOUNCES 2017 HALF YEAR RESULTS
21/09/2017
Regulated information MIThRA ANNOUNCES 2017 HALF YEAR RESULTS Liège, Belgium, 21 September 2017 - Mithra (Euronext Brussels: MITRA), a company specialized in women's health, today announces its financial results for the [...]
Biocartis Group NV: Disclosure of a transparency notification
21/09/2017
PRESS RELEASE: REGULATED INFORMATION 21 September 2017, 07:00 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]
La fondation Dangote et GBCHealth unissent leurs forces pour construire une coalition autour de la santé
21/09/2017
NEW YORK, le 21 septembre 2017 (GLOBE NEWSWIRE) - La fondation Dangote ( www.Dangote.com ) et GBCHealth ont uni leurs forces pour donner naissance à un nouveau modèle de partenariat, l'African Business Coalition on [...]
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
21/09/2017
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug [...]
ProtectMyPeople - A New Group Life Insurance Comparison Site - Launches for UK Small and Medium Business Owners
20/09/2017
Price comparison experts, the idol.com have launched the UK's first ever price comparison site for "Death in Service" insurance ProtectMyPeople aims to make group employee benefits more accessible for business owners. [...]
GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2)
20/09/2017
GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2) Alerte initiale sur un risque potentiel d'erreur médicale [...]
GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor
20/09/2017
GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor Initial alert on potential medication error raised by Prescrire , an independent [...]
Summit Therapeutics plc : Holding(s) in Company
20/09/2017
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics [...]
Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board
20/09/2017
Synthego strengthens position with appointment while accelerating worldwide commercial growth REDWOOD CITY, CA--(Marketwired - Sep 20, 2017) - Synthego , a leading provider of genome engineering solutions, announces the [...]
Optalysys, Ltd. Raises $4 Million Seed Round to Break Bottlenecks in Genomic Research and Big Data Analysis
20/09/2017
Light-Speed Optical Processing Startup to Democratize Access to High-Powered Computing and Drive Advances in Research and Development GLASSHOUGHTON, WEST YORKSHIRE, United Kingdom and RENO, Nev., Sept. 20, 2017 (GLOBE [...]
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
20/09/2017
ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
20/09/2017
AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its [...]
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
20/09/2017
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy - Investigational RNAi Therapeutic Patisiran Meets Primary [...]
Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine
20/09/2017
Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine - L'agent thérapeutique [...]
Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer
20/09/2017
Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer London (UK) - 20 September, 2017: Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal [...]
Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD
20/09/2017
Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD Topline results revealed the study met its primary [...]
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
20/09/2017
Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM in the EU, Rydapt offers a new [...]

Pages